Product Program year 2025 Source: CMS Open Payments

Amtagvi

Drug Oncology

NDC 73776-001-12

Open in the dashboard

General payments

$258,094

3,620 payments

Research payments

$19,867,204

2,670 payments

Through program year 2025, $258,094 in general payments and $19,867,204 in research payments were reported against Amtagvi (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2025 General $143,387 3,016
2025 Research $13,366,776 1,844
2024 General $114,708 604
2024 Research $6,500,427 826

Breakdown

Who paid General payments · program years 2024–2025
  1. Iovance Biotherapeutics, Inc. $258,094 3,620 payments
Top recipients General payments · program year 2025
  1. Joel Neal Medical Oncology · Stanford, CA $10,875 8% · 3 payments
  2. Genevieve Boland Surgical Oncology · Boston, MA $8,220 6% · 2 payments
  3. Daniel Olson Hematology & Oncology · Chicago, IL $6,804 5% · 6 payments
  4. Justin Moser Internal Medicine · Scottsdale, AZ $6,115 4% · 6 payments
  5. Janice Dutcher New York, NY $4,375 3% · 2 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Hematology & Oncology Internal Medicine $37,449 27% · 653 practitioners
  2. Medical Oncology Internal Medicine $30,600 22% · 208 practitioners
  3. Surgical Oncology Surgery $13,105 10% · 35 practitioners
  4. Internal Medicine $11,350 8% · 40 practitioners
  5. Nurse Practitioner, Family Nurse Practitioner $11,099 8% · 359 practitioners

The top 5 of 87 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $22,430 16% · 287 recipients
  2. New York $14,042 10% · 66 recipients
  3. Florida $12,888 9% · 299 recipients
  4. Massachusetts $8,928 6% · 13 recipients
  5. Arizona $8,701 6% · 77 recipients

The top 5 of 48 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

3,620 general · 2,670 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record